Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Circulation

Volumn 118, Issue 22, 2008, Pages 2259-2267

  Davis, Barry R ^a   Kostis, John B ^b   Simpson, Lara M ^a   Black, Henry R ^c   Cushman, William C ^d   Einhorn, Paula T ^e   Farber, Michael A ^f   Ford, Charles E ^a   Levy, Daniel ^e   Massie, Barry M ^g   Nawaz, Shah ^h  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Crozer Keystone Health System   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h NONE

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive agents; Calcium channel blockers; Diuretics; Heart failure; Hypertension; Ventricular ejection fraction

Indexed keywords

AMLODIPINE; ATENOLOL; CHLORTALIDONE; CLONIDINE; DOXAZOSIN; LISINOPRIL; RADIOISOTOPE; RESERPINE;

ADULT; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; DOXAZOSIN; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PROGNOSIS; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL ANALYSIS; SURVIVORS; UNITED STATES;

EID: 57749189570     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.762229     Document Type: Article

References (45)

1. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Research Group. Am J Hypertens. 1996;9:342-360.
2. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 1 (ALLHAT): ALLHAT Collaborative Research Group. JAMA. 2000;283:1967-1975.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
4. Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol. 2001;38:1295-1296.
5. Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens. 2003;5:9-13.
6. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR, for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J. 2007;153:42-53.
7. Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med. 1997;241:387-394.
8. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
9. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
10. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.
11. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J. 1999;20:447-455.
12. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL, for the Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or= 65 years of age: CHS Research Group: Cardiovascular Health Study. Am J Cardiol. 2001;87:413-419.
13. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R, Fabsitz RR, Howard BV. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000;86:1090-1096.
14. McDermott MM, Feinglass J, Lee PI, Mehta S, Schmitt B, Lefevre F, Gheorghiade M. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J. 1997;134:728-736.
15. Peyster E, Norman J, Domanski M. Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. J Card Fail. 2004;10:49-54.
16. Dauterman KW, Go AS, Rowell R, Gebretsadik T, Germer S, Massie BM. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:221-228.
17. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510-1518.
18. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function: the Cardiovascular Health Study. Ann Intern Med. 2002;137:631-639.
19. Redfield MM. Understanding "diastolic" heart failure. N Engl J Med. 2004;350:1930-1931.
20. Konstam MA. "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. J Card Fail. 2003;9:1-3.
21. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
22. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000.
23. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
24. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;49:972-981.
25. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 1990;81(suppl):III-1-III-7.
26. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144-2150.
27. Aurigemma GP, Gaasch WH. Clinical practice: diastolic heart failure. N Engl J Med. 2004;351:1097-1105.
28. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
29. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure Circulation. 2005;111:2306-2312.
30. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781.
31. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973.
32. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
33. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207.
34. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
35. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17-22.
36. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005;11:177-187.
37. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277-283.
38. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002;8:279-287.
39. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112:437-445.
40. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393.
41. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? N Rev Drug Discov. 2007;6:127-139.
42. Hawkins NM, Wang D, McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG, for the CHARM Investigators and Committees. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart. 2007;93:59-64.
43. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA. 1997;278:212-216.
44. Kitzman DW. Therapy for diastolic heart failure: on the road from myths to multicenter trials. J Card Fail. 2001;7:229-231.
45. Asselbergs FW, van Gilst WH. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Curr Opin Cardiol. 2007;22:267-272.